Treatment effect of ex vivo expanded allogeneic bone marrow–derived mesenchymal stem cells for the treatment of fistulizing Crohn disease are durable at 12 months
Mesenchymal stem cells have been administered via direct injection to treat perianal Crohn fistulizing disease. We herein sought to determine the safety and durability of treatment response to 12 months with 3 individual phase IB/IIA clinical trials of mesenchymal stem cells for refractory perianal, rectovaginal, and ileal pouch fistulas in the setting of Crohn disease.
Source: Surgery - Category: Surgery Authors: Amy L. Lightner, Ana Otero Pineiro, Jane Reese, Justin Ream, Douglas Nachand, Ashley C. Adams, Neda Dadgar, Tracy Hull Source Type: research
More News: Clinical Trials | Crohn's Disease | Inflammatory Bowel Disease | Stem Cell Therapy | Stem Cells | Surgery